Endocyte to Present at the Ladenburg Thalmann 2016 Healthcare Conference
September 20 2016 - 4:01PM
Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small
molecule drug conjugates (SMDCs) and companion imaging agents for
personalized therapy, today announced that the company’s management
team will present at the Ladenburg Thalmann 2016 Healthcare
Conference on Tuesday, Sept. 27th, at 11:00 a.m. EDT. The
conference will be held at the Sofitel New York in New York City.
A live audio webcast of the Company’s presentation can be
accessed by visiting “Events & Presentations” under the
Investors & News section of Endocyte’s website at
www.endocyte.com. The webcast will be archived shortly after the
live event, and a replay will be available on the Company’s website
for 90 days following the conference.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing
targeted therapies for the treatment of cancer and other serious
diseases. Endocyte uses its proprietary drug conjugation
technology to create novel SMDCs and companion imaging agents for
personalized targeted therapies. The company’s SMDCs actively
target receptors that are over-expressed on diseased cells,
relative to healthy cells. This targeted approach is designed
to enable the treatment of patients with highly active drugs at
greater doses, delivered more frequently and over longer periods of
time than would be possible with the untargeted drug alone.
The companion imaging agents are designed to identify patients
whose disease over-expresses the target of the therapy and who are
therefore more likely to benefit from treatment. For additional
information, please visit Endocyte’s website at
www.endocyte.com.
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endocyte, Inc. (delisted) (NASDAQ:ECYT)
Historical Stock Chart
From Apr 2023 to Apr 2024